The mechanisms responsible for drug resistance in SCLC are mainly summarized as follows: The key molecular pathways involved in the transformation of SCLC to a NE-low phenotype include YAP1, NOTCH, Wnt family (WNT), and MYC signaling, all of which contribute to drug resistance in SCLC. Here, YAP1 is linked to small cell lung carcinoma.